Clive Meanwell Bets on AI to Scout Next Big Biotech
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Clive Meanwell, an onetime oncologist with nearly four decades in drug development and biotech investing, serves as chairman and partner at Population Health Partners.
- Population Health Partners scouts the biggest problems in human health and backs companies whose technologies, business models, molecules, or diagnostics could solve them.
- Metsera, an obesity startup, triggered a bidding war that escalated from Pfizer's initial $7.3 billion offer to Novo Nordisk's unsolicited $9 billion bid and then a $10 billion counteroffer.
- Meanwell called the escalating Metsera bidding war "an investor's dream" and said he is now betting on AI to help him identify similar opportunities again.
- The profile is published as exclusive content for STAT+ subscribers.
Why it matters: Meanwell, who sat on the winning side of the Metsera bidding war that drove offers from $7.3B to $10B, is now layering AI onto Population Health Partners' problem-first approach — a sign that algorithmic deal-sourcing is entering a sector long defined by personal networks and clinical intuition.
